Alicia Bigica

The latest generic entry comes on the heels of a new report from ICER, which published a list of prescription drugs that had substantial price increases in 2017 and 2018 without what they consider to be new supporting evidence.

The oral selective adenosine A 2A receptor antagonist was approved in August as adjunctive treatment to levodopa/carbidopa for patients with Parkinson disease who experience off episodes.

The findings have implications for ongoing early intervention research in Alzheimer disease and dementia since significant functional and neurocognitive declines were evident in middle age adults based on gait speed assessments.

New classes of acute migraine therapies on the cusp of FDA approval look to fill in long-standing gaps in care.

The latest generic entry comes on the heels of a new report from ICER, which published a list of prescription drugs that had substantial price increases in 2017 and 2018 without what they consider to be new supporting evidence.

The centers will make all data freely available to the greater research community, including those in academia and industry.

Bernard Baumel, MD, and colleagues at the University of Miami have recently launched a clinical trial to examine the safety and efficacy of multiple doses of human mesenchymal stem cells in patients with Alzheimer disease.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Fred Rincon, MD, MSc.

Hauser, who is director of the UCSF Weill Institute for Neurosciences, spoke with NeurologyLive about the gravity of the phase 3 ASCLEPIOS I and II trial results in relapsing MS.

New classes of acute migraine therapies on the cusp of FDA approval look to fill in long-standing gaps in care.

The drug, the only approved botulinum toxin type B on the market, was recently approved for the treatment of chronic sialorrhea in adults.

The study included patients with Parkinson disease receiving treatment with levodopa carbidopa who experienced morning akinesia.

While AAN makes a push for annual cognitive assessments in older adults, the USPSTF found that there is not enough evidence to support routine screening.

The phase 3 clinical trial program included 2 identical, multicenter, double-blind, and placebo-controlled trials of the BACE inhibitor intended for the treatment of early Alzheimer disease.

The 1st Annual Congress on the Future of Neurology will take place September 27-28, 2019 at the InterContinental New York Times Square in New York City.

Wave Life Sciences intends to file for accelerated approval in the second half of 2020 pending muscle biopsy results from an open-label extension study.

The 1st Annual Congress on the Future of Neurology will take place September 27-28, 2019 at the InterContinental New York Times Square in New York City.

Nearly 87% of patients enrolled in the phase 3b CASTING study had no evidence of disease activity following treatment with ocrelizumab after having an inadequate response to prior DMTs.

The phase 3 clinical trial program included 2 identical, multicenter, double-blind, and placebo-controlled trials of the BACE inhibitor intended for the treatment of early Alzheimer disease.

Rodney Allan Radtke, MD, professor of neurology at Duke University School of Medicine in Durham, North Carolina, discussed some of the new therapeutic options available to help improve tolerance and adherence challenges that clinicians commonly face in epilepsy practice.

The humanized monoclonal antibody was particularly effective in patients who were seropositive for aquaporin-4 autoantibodies.

The drug is currently approved for the treatment of Parkinson disease-related psychosis, and is also being explored in schizophrenia and major depressive disorder.

The confirmatory phase 2 study by Neurotrope sought to assess the safety, efficacy, and tolerability of intravenous Bryostatin-1 20µg in 108 participants with AD who were not taking memantine.

Given that ICH is associated with some of the worst outcome rates among stroke subtypes, investigators sought to evaluate the effect of improved implementation of a system of evidence- and guideline-based interventions.

Rodney Allan Radtke, MD, professor of neurology at Duke University School of Medicine in Durham, North Carolina, discussed some of the new therapeutic options available to help improve tolerance and adherence challenges that clinicians commonly face in epilepsy practice.

Data from the phase 3b FOCUS trial demonstrates fremanezumab’s superior efficacy and tolerability in the prevention of migraine.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Reisa Sperling, MD.

Data from the phase 3b FOCUS trial demonstrates fremanezumab’s superior efficacy and tolerability in the prevention of migraine.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Reisa Sperling, MD.